Extended-spectrum β-lactamases (ESBLs) are a group of plasmid-mediated, diverse,
complex and rapidly evolving enzymes that are posing a major therapeutic challenge today …

Since first reported in Europe in the early 1980s, extended-spectrum β-lactamases (ESBLs)
have spread worldwide. When producing these broad-spectrum plasmid-encoded enzymes …

Extended-spectrum β-lactamase (ESBL) producing gram-negative bacilli are a growing
concern in human medicine today. When producing these enzymes, organisms (mostly K …

Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases
which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are …

Extended-spectrum b-lactamases (ESBLs) are enzymes produced by gram-negative bacilli
that have the ability to inactivate b-lactam antibiotics containing an oxyimino group (ie …

Extended-spectrum β-lactamases (ESBLs) are plasmid-mediated bacterial enzymes that
confer resistance to a broad range of β-lactams. They are descended by genetic mutation …

The acronym ESBL (extended-spectrum/-lactamase), usually applied to Klebsiella
pneumoniae, has joined MRSA (methicillinresistant Staphylococcus aureus) and VRE …

Extended-spectrum b-lactamases (ESBLs) form a heterogeneous group that share the
property of hydrolytic activity against the oxyimino-b-lactams while remaining susceptible to …

Extended spectrum β-lactamases (ESBLs) are plasmid mediated, TEM and SHV derived
enzymes, first isolated in Western Europe in mid 1980s, most commonly in Klebsiella spp …

Extended spectrum β-lactamase (ESBL)-producing organisms pose unique challenges to
clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery …